Saltar al contenido
Merck
Todas las fotos(1)

Documentos clave

Ver Toda la documentación

SML0212

Sigma-Aldrich

PSB36

≥98% (HPLC)

Sinónimos:

1-Butyl-3-(3-hydroxypropyl)-8-(3-noradamantyl)xanthine, 1-Butyl-8-(hexahydro-2,5-methanopentalen-3a(1H)-yl)-3,9-dihydro-3-(3-hydroxypropyl)-1H-purine-2,6-dione, PSB-36

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Todas las fotos(1)

About This Item

Fórmula empírica (notación de Hill):
C21H30N4O3
Número de CAS:
524944-72-7
Peso molecular:
386.49
Código UNSPSC:
12352200
ID de la sustancia en PubChem:
329825233
NACRES:
NA.77

Nivel de calidad

100

Ensayo

≥98% (HPLC)

Formulario

powder

condiciones de almacenamiento

desiccated

color

white to tan

solubilidad

DMSO: ≥20 mg/mL

temp. de almacenamiento

2-8°C

cadena SMILES

CCCCN1C(=O)N(CCCO)c2nc([nH]c2C1=O)C34C[C@@H]5C[C@@H](C[C@H]3C5)C4

InChI

1S/C21H30N4O3/c1-2-3-5-25-18(27)16-17(24(20(25)28)6-4-7-26)23-19(22-16)21-11-13-8-14(12-21)10-15(21)9-13/h13-15,26H,2-12H2,1H3,(H,22,23)/t13-,14+,15-,21-

Clave InChI

CIBIXJYFYPFMTN-FZUGUKJMSA-N

Aplicación

PSB36 was used to examine the role of A1-adenosine receptor-mediated cell signaling in CD39 expression in pancreatic b-cells of streptozotocin-induced diabetic mice.

Acciones bioquímicas o fisiológicas

Inhibition of A1 adenosine receptor by PSB36 modulates the spinal antinociception in animal models.
PSB36 is a very potent, selective antagonist of the adenosine A1 receptor. The compound selectivity (Ki) for human A1, A2A, A2B and A3 receptors is 0.7, 980, 187 and 2300 respectively. PSB36 is considerably more potent that DPCPX (EC50 0.012 nM vs 2.9 nM)
PSB36 is an adenosine A1 AR antagonist

Características y beneficios

This compound is featured on the Adenosine Receptors page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

Código de clase de almacenamiento

11 - Combustible Solids

Clase de riesgo para el agua (WGK)

WGK 3

Punto de inflamabilidad (°F)

Not applicable

Punto de inflamabilidad (°C)

Not applicable

Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number
111M4613V

¿No ve la versión correcta?

Si necesita una versión concreta, puede buscar un certificado específico por el número de lote.

Busque por un COA

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Yuta Tanaka et al.
Biological & pharmaceutical bulletin, 43(3), 516-525 (2019-12-24)
It is therapeutically important to elucidate the factors involved in the radiation resistance of tumors. We previously showed that ATP is released from mouse melanoma B16 cells in response to γ-irradiation, but the role of adenosine, a metabolite of ATP
Siqi Chen et al.
Cancer immunology research, 8(8), 1064-1074 (2020-05-10)
Accumulating evidence suggests that inhibiting adenosine-generating ecto-enzymes (CD39 and CD73) and/or adenosine A2A or A2B receptors (R) stimulates antitumor immunity and limits tumor progression. Although activating A2ARs or A2BRs causes similar immunosuppressive and protumoral functions, few studies have investigated the
Osama M Abo-Salem et al.
The Journal of pharmacology and experimental therapeutics, 308(1), 358-366 (2003-10-18)
Caffeine, an adenosine A1, A2A, and A2B receptor antagonist, is frequently used as an adjuvant analgesic in combination with nonsteroidal anti-inflammatory drugs or opioids. In this study, we have examined the effects of novel specific adenosine receptor antagonists in an
Luca Soattin et al.
Frontiers in physiology, 11, 493-493 (2020-07-01)
Adenosine leads to atrial action potential (AP) shortening through activation of adenosine 1 receptors (A1-R) and subsequent opening of G-protein-coupled inwardly rectifying K+ channels. Extracellular production of adenosine is drastically increased during stress and ischemia. The aim of this study
Kazuki Kitabatake et al.
Biological & pharmaceutical bulletin, 44(2), 197-210 (2020-12-04)
Glioblastoma is the most common malignant tumor of the central nervous system and is treated with a combination of surgery, radiation and chemotherapy. However, the tumor often acquires radiation resistance, which is characterized by an increased DNA damage response (DDR).
Ver todos los artículos relacionados

Artículos

Adenosine Receptors

We offers many products related to adenosine receptors for your research needs.

Adenosine Receptors

We offers many products related to adenosine receptors for your research needs.

Adenosine Receptors

We offers many products related to adenosine receptors for your research needs.

Adenosine Receptors

We offers many products related to adenosine receptors for your research needs.

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico